Search | Clinical Trials Finder

Conditions: Urticaria
Interventions: abatacept (Orencia ®); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Pruritus of Unknown Origin
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: Savannah, Georgia • Indianapolis, Indiana • Boardman, Ohio + 1 more

Conditions: Uremic Pruritus
Interventions: CR845 0.5 mcg/kg; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 33
States / cities: Escondido, California • Riverside, California • San Diego, California + 26 more

Conditions: Atopic Dermatitis
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 28
States / cities: Encinitas, California • Encino, California • Lomita, California + 22 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Briquilimab, Placebo; Drug · Other
Lead sponsor: Jasper Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more

Conditions: Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
Interventions: nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID, Placebo tablets BID; Drug
Lead sponsor: Trevi Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Chronic Pruritus
Interventions: VPD-737, Placebo; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 25
States / cities: Fremont, California • Lomita, California • Redwood City, California + 21 more

Conditions: Uremic Pruritus
Interventions: CR845 0.5 mcg/kg, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 57
States / cities: Homewood, Alabama • Huntsville, Alabama • Bakersfield, California + 52 more

Conditions: Chronic Kidney Diseases, Pruritus
Interventions: Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: Northridge, California • Miami, Florida • Miami Lakes, Florida + 5 more

Conditions: Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 132
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 104 more

Conditions: Moderate to Severe Chronic Plaque-type Psoriasis
Interventions: secukinumab low dose, secukinumab high dose; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more

Conditions: Uremic Pruritus
Interventions: PA101B, Placebo; Drug
Lead sponsor: Patara Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 13
States / cities: Phoenix, Arizona • Pine Bluff, Arkansas • Northridge, California + 10 more

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064 (blinded), placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 11
States / cities: Bakersfield, California • San Diego, California • Miami, Florida + 8 more

Conditions: Chronic Spontaneous Urticaria
Interventions: LOU064 (blinded), Placebo, LOU064 (open label); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 43
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 38 more

Conditions: Chronic Pruritus, Atopic Dermatitis
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 28
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 23 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 38
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 31 more

Conditions: Pruritus
Interventions: 5 mg Serlopitant Tablets, Matching Placebo Tablets; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 41
States / cities: Hot Springs, Arkansas • Bakersfield, California • Fremont, California + 36 more

Conditions: Chronic Inducible Urticaria
Interventions: Ligelizumab, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Evansville, Indiana • North Charleston, South Carolina • El Paso, Texas + 1 more

Conditions: Psoriasis
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 50
States / cities: Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more

Conditions: Chronic Pruritus of Unknown Origin
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: Tampa, Florida • Brighton, Massachusetts • Clarkston, Michigan + 1 more

Conditions: Pruritus, Kidney Failure, Chronic, Hemodialysis, Chronic Disease
Interventions: Not listed
Lead sponsor: Acologix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Augusta, Georgia • Metaire, Louisiana • Springfield, Massachusetts + 2 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 12 more

Conditions: Uremic Pruritus, Pruritus
Interventions: nalbuphine HCl ER; Drug
Lead sponsor: Trevi Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 35
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more

Conditions: Cutaneous Nerves CNS Itch
Interventions: Clonidine, Naltrexone; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

VPD-737 for Treatment of Chronic Pruritus

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Treatment of Uremic Pruritus With PA101B

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

An Observational Study of Pruritus Amongst Hemodialysis Patients

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function